(BNGO) Bionano Genomics - Ratings and Ratios
Genomic Systems, Instruments, Software
BNGO EPS (Earnings per Share)
BNGO Revenue
Description: BNGO Bionano Genomics October 20, 2025
Bionano Genomics Inc. (NASDAQ: BNGO) delivers end-to-end genome-analysis solutions that combine proprietary optical genome-mapping hardware (Saphyr and Stratys systems), consumables (chips, prep kits, labeling kits), and software (VIA, analysis platforms) to detect structural variations and other causal variants. The company also offers a suite of diagnostic services-including chromosomal microarray, Fragile X, exome sequencing, and whole-genome SV tests-for rare-disease and prenatal applications, serving labs across the Americas, EMEA, and APAC.
According to the most recent quarterly filing (Q3 2024), BNGO reported revenue of $23.5 million, a 38 % year-over-year increase, driven primarily by growth in consumable sales and the rollout of its OGM-Dx diagnostic portfolio. The balance sheet showed $115 million in cash and short-term investments, providing runway for R&D and commercial expansion without immediate dilution risk. Gross margin expanded to 68 % versus 62 % in the prior year, reflecting economies of scale in chip production and higher-margin software licensing.
Key macro drivers for Bionano’s market include the accelerating adoption of precision-medicine workflows that require accurate structural-variant detection-an area where short-read sequencing is less effective-and the projected $15 billion global market for optical genome mapping by 2028, growing at a CAGR of roughly 20 %. Competitive pressure from long-read sequencing platforms (e.g., PacBio, Oxford Nanopore) and the need for reimbursement clarity in rare-disease diagnostics represent material uncertainties that could affect BNGO’s upside.
If you’re looking to deepen your quantitative analysis of BNGO’s valuation metrics and scenario modeling, a quick look at ValueRay’s data dashboards can help you surface the most relevant financial levers without the noise.
BNGO Stock Overview
| Market Cap in USD | 19m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2018-08-21 |
BNGO Stock Ratings
| Growth Rating | -94.4% |
| Fundamental | 29.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -92.1% |
| Analyst Rating | 3.50 of 5 |
BNGO Dividends
Currently no dividends paidBNGO Growth Ratios
| Growth Correlation 3m | -64.6% |
| Growth Correlation 12m | -85.3% |
| Growth Correlation 5y | -94% |
| CAGR 5y | -89.27% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.89 |
| CAGR/Mean DD 3y (Pain Ratio) | -1.02 |
| Sharpe Ratio 12m | -0.75 |
| Alpha | -129.06 |
| Beta | 2.196 |
| Volatility | 63.62% |
| Current Volume | 162.6k |
| Average Volume 20d | 377.6k |
| Stop Loss | 1.5 (-11.2%) |
| Signal | -0.68 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-74.3m TTM) > 0 and > 6% of Revenue (6% = 1.65m TTM) |
| FCFTA -0.34 (>2.0%) and ΔFCFTA 51.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 67.40% (prev 63.95%; Δ 3.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.34 (>3.0%) and CFO -26.1m > Net Income -74.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.44m) change vs 12m ago 199.5% (target <= -2.0% for YES) |
| Gross Margin 6.75% (prev 28.97%; Δ -22.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 26.71% (prev 28.28%; Δ -1.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -324.0 (EBITDA TTM -68.9m / Interest Expense TTM 253.0k) >= 6 (WARN >= 3) |
Altman Z'' -58.03
| (A) 0.24 = (Total Current Assets 42.7m - Total Current Liabilities 24.2m) / Total Assets 76.0m |
| (B) -9.25 = Retained Earnings (Balance) -703.2m / Total Assets 76.0m |
| warn (B) unusual magnitude: -9.25 — check mapping/units |
| (C) -0.80 = EBIT TTM -82.0m / Avg Total Assets 102.7m |
| (D) -22.95 = Book Value of Equity -703.2m / Total Liabilities 30.6m |
| Total Rating: -58.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.31
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin -95.03% = -7.50 |
| 4. Debt/Equity 0.43 = 2.41 |
| 5. Debt/Ebitda -0.23 = -2.50 |
| 7. RoE -167.2% = -2.50 |
| 8. Rev. Trend -37.16% = -2.79 |
| 9. EPS Trend -66.31% = -3.32 |
What is the price of BNGO shares?
Over the past week, the price has changed by -7.14%, over one month by -17.16%, over three months by -44.59% and over the past year by -90.61%.
Is Bionano Genomics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BNGO is around 1.82 USD . This means that BNGO is currently overvalued and has a potential downside of 7.69%.
Is BNGO a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BNGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.5 | 462.1% |
| Analysts Target Price | 9.5 | 462.1% |
| ValueRay Target Price | 2 | 18.3% |
BNGO Fundamental Data Overview October 28, 2025
P/S = 0.6812
P/B = 0.4032
Beta = 2.196
Revenue TTM = 27.4m USD
EBIT TTM = -82.0m USD
EBITDA TTM = -68.9m USD
Long Term Debt = 7.82m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.4m USD (from shortTermDebt, last quarter)
Debt = 19.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.0m USD (from netDebt column, last quarter)
Enterprise Value = 21.8m USD (18.7m + Debt 19.6m - CCE 16.4m)
Interest Coverage Ratio = -324.0 (Ebit TTM -82.0m / Interest Expense TTM 253.0k)
FCF Yield = -119.4% (FCF TTM -26.1m / Enterprise Value 21.8m)
FCF Margin = -95.03% (FCF TTM -26.1m / Revenue TTM 27.4m)
Net Margin = -271.0% (Net Income TTM -74.3m / Revenue TTM 27.4m)
Gross Margin = 6.75% ((Revenue TTM 27.4m - Cost of Revenue TTM 25.6m) / Revenue TTM)
Gross Margin QoQ = 51.64% (prev 52.72%)
Tobins Q-Ratio = 0.29 (Enterprise Value 21.8m / Total Assets 76.0m)
Interest Expense / Debt = 0.37% (Interest Expense 73.0k / Debt 19.6m)
Taxrate = -0.15% (negative due to tax credits) (10.0k / -6.85m)
NOPAT = -82.1m (EBIT -82.0m * (1 - -0.15%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.76 (Total Current Assets 42.7m / Total Current Liabilities 24.2m)
Debt / Equity = 0.43 (Debt 19.6m / totalStockholderEquity, last quarter 45.4m)
Debt / EBITDA = -0.23 (negative EBITDA) (Net Debt 16.0m / EBITDA -68.9m)
Debt / FCF = -0.61 (negative FCF - burning cash) (Net Debt 16.0m / FCF TTM -26.1m)
Total Stockholder Equity = 44.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -97.79% (Net Income -74.3m / Total Assets 76.0m)
RoE = -167.2% (Net Income TTM -74.3m / Total Stockholder Equity 44.5m)
RoCE = -156.8% (out of range, set to none) (EBIT -82.0m / Capital Employed (Equity 44.5m + L.T.Debt 7.82m))
RoIC = -150.9% (out of range, set to none) (NOPAT -82.1m / Invested Capital 54.4m)
WACC = 7.08% (E(18.7m)/V(38.3m) * Re(14.11%) + D(19.6m)/V(38.3m) * Rd(0.37%) * (1-Tc(-0.00)))
Discount Rate = 14.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 125.3%
Fair Price DCF = unknown (Cash Flow -26.1m)
EPS Correlation: -66.31 | EPS CAGR: -6.75% | SUE: -0.53 | # QB: 0
Revenue Correlation: -37.16 | Revenue CAGR: -2.51% | SUE: 0.17 | # QB: 0
Additional Sources for BNGO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle